A company should invest in a dedicated regulatory intelligence function when regulatory changes begin to directly affect product timelines, market access, or strategic decisions. For most biopharmaceutical and medical device companies, this point arrives earlier than expected. The sections below break down the key signals, the build-versus-outsource question, and how to get started without a large budget.
What does a dedicated regulatory intelligence function actually do?
A dedicated regulatory intelligence function monitors, interprets, and communicates regulatory developments that affect a company’s products, pipelines, and markets. It tracks guidance documents, legislative changes, agency announcements, and enforcement trends, then translates that information into actionable insights that shape strategy, submissions, and compliance decisions.
In practice, this means the function covers several interconnected activities:
- Horizon scanning: Continuously tracking updates from regulators such as the EMA, FDA, and national competent authorities
- Impact assessment: Evaluating how new or revised requirements apply to specific products or development programs
- Competitive benchmarking: Reviewing publicly available regulatory decisions to understand approval trends and agency expectations
- Internal communication: Briefing R&D, quality, and commercial teams on changes that require a response
- Regulatory strategy support: Informing go/no-go decisions, target product profiles, and submission planning based on the current regulatory environment
Without this function, companies often react to regulatory changes after the fact, which leads to costly rework, delayed submissions, and missed market opportunities.
What are the early signs a company needs dedicated regulatory intelligence?
The clearest early sign is when your team regularly discovers regulatory changes after they have already affected a project. Other signals include spending significant time searching for guidance updates, receiving unexpected questions from regulators that could have been anticipated, or making strategic decisions without a clear picture of the current regulatory landscape.
Additional warning signs worth taking seriously include:
- Your regulatory affairs team is too busy with submissions to monitor evolving requirements
- You operate across multiple markets and struggle to keep pace with different regulatory timelines
- A competitor received approval faster, partly because they anticipated a regulatory shift you missed
- Your product development roadmap has been revised more than once due to unanticipated regulatory changes
- Investors or partners are asking questions about regulatory risk that your team cannot answer confidently
For early-stage companies, these signs often emerge during the transition from a single-product focus to a broader pipeline or a multi-market strategy. At that point, informal monitoring is no longer sufficient.
How does company size affect the decision to invest in regulatory intelligence?
Company size shapes the form of the investment more than the need for it. Small and early-stage companies still need regulatory intelligence, but they typically cannot justify a full in-house team. Larger companies with complex pipelines and multiple markets can support dedicated internal resources, while mid-sized companies often benefit most from a hybrid approach.
For startups and small companies, the priority is access to timely, relevant intelligence without the overhead of a full function. This often means designating a regulatory lead who builds monitoring into their existing role, supplemented by external expertise for deeper analysis.
Mid-sized companies with growing pipelines tend to reach a tipping point where the volume and complexity of regulatory activity justifies a dedicated person or small team. At this stage, the cost of missed intelligence often exceeds the cost of the resource.
Large companies with global portfolios typically invest in structured regulatory intelligence teams with defined workflows, subscription-based monitoring tools, and formal processes for disseminating intelligence across functions. The investment at this scale is primarily about coordination and ensuring consistent application of intelligence across the organization.
What’s the difference between regulatory intelligence and regulatory affairs?
Regulatory affairs focuses on preparing and submitting applications, maintaining approvals, and ensuring ongoing compliance with known requirements. Regulatory intelligence focuses on what is changing, what is coming, and what it means for strategy. One is primarily operational; the other is primarily forward-looking and analytical.
Think of it this way: regulatory affairs answers the question “are we meeting current requirements?” while regulatory intelligence answers “what will the requirements be, and are we prepared for them?”
In practice, the two functions are closely connected. Good regulatory intelligence feeds directly into regulatory strategy, which in turn shapes the work of regulatory affairs. In smaller companies, the same person often handles both, but as organizations grow, separating these responsibilities allows each to be done more thoroughly. Regulatory affairs professionals benefit enormously from having reliable intelligence, because it reduces surprises and allows submissions to be built on a current understanding of agency expectations.
Should a company build an in-house regulatory intelligence team or outsource it?
The right answer depends on the volume and complexity of regulatory activity your company faces. Building in-house makes sense when regulatory intelligence is a continuous, high-volume need tied directly to strategic decisions. Outsourcing is more appropriate when the need is periodic, when the company lacks the internal expertise to build the function, or when budget constraints make a full-time hire difficult to justify.
Reasons to build in-house
An internal team develops deep familiarity with your specific products, therapeutic areas, and strategic priorities. Intelligence is integrated directly into decision-making processes, and institutional knowledge accumulates over time. This approach works best when you have a broad pipeline, operate in multiple regulated markets, and need intelligence to flow continuously into R&D, quality, and commercial planning.
Reasons to outsource
External regulatory intelligence partners bring ready-made expertise, established monitoring systems, and broad cross-industry visibility that a new in-house team takes years to develop. For early-stage companies or those entering a new market or product category, outsourcing provides immediate access to high-quality intelligence without the lead time of building internal capability. It also allows you to scale the service up or down based on your current needs.
How can a company start building regulatory intelligence capabilities on a limited budget?
Start by identifying the two or three regulatory bodies most relevant to your current products and markets, then set up structured monitoring for those agencies specifically. Free resources from the EMA, FDA, and national competent authorities, combined with a simple internal process for reviewing and distributing updates, form a functional starting point that costs very little.
Practical steps for a resource-constrained approach include:
- Subscribe to official agency newsletters and RSS feeds from the regulators that matter most to your pipeline
- Assign ownership of regulatory monitoring to a specific person, even if it is only a portion of their role
- Create a simple log of relevant updates, their potential impact, and any actions required
- Schedule a regular review of the log with key stakeholders, such as a monthly 30-minute meeting with R&D and quality leads
- Use external consultants selectively for deeper analysis when a significant change requires interpretation beyond your internal expertise
The goal at an early stage is not a comprehensive intelligence system but a reliable habit of staying informed. Even a basic, consistent process significantly reduces the risk of being caught off guard by regulatory changes that affect your timelines or market access.
How Starodub supports your regulatory intelligence needs
We work with biopharmaceutical and medical device companies at every stage, from early development through post-market, to ensure regulatory changes never become unexpected roadblocks. Our team brings deep experience across EU regulatory frameworks, including evolving requirements for medicinal products, biologics, ATMPs, and medical devices under the MDR and IVDR.
Here is what we offer in practice:
- Regulatory horizon scanning: We monitor the EMA, national competent authorities, and relevant EU legislative developments on your behalf and translate updates into clear, product-specific implications
- Regulatory strategy advice: We help you build or refine your regulatory strategy based on the current and anticipated regulatory environment, not assumptions from two years ago
- Flexible support models: Whether you need a one-off regulatory landscape assessment or ongoing intelligence support integrated into your development program, we scale our involvement to your actual needs and budget
- Cross-functional communication: We communicate regulatory intelligence in plain language to your R&D, quality, and leadership teams, ensuring the right people have the information they need to make sound decisions
- Early-stage guidance: For startups and growing companies, we provide practical, resource-conscious regulatory support that builds a strong foundation without overextending your budget
If regulatory changes are affecting your timelines or you are not confident your team has full visibility of what is coming, reach out to us at Starodub to discuss how we can support your regulatory intelligence needs.
Related Articles
- How does Phase I to Phase III strategy differ?
- How does GMP compliance work in pharmaceutical manufacturing?
- What is regulatory strategy governance and how do you implement it?
- What are EMA requirements?
- Can small biotech companies handle regulatory affairs internally?
This content was generated with the help of AI and it may contain mistakes
